Cutaneous Eruptions in the Course of COVID-19 Among Geriatric Patients in a Nursing Home in Poland

Figures & data

Figure 1 Timeline showing the most significant events in Case 1.

Figure 2 Timeline showing the most significant events in Case 2.

Figure 3 Timeline showing the most significant events in Case 3.

Figure 4 Timeline showing the most significant events in Case 4.

Figure 5 Timeline showing the most significant events in Case 5.

Figure 6 Photographs of skin manifestations in presented cases (A) Case 1; (B) Case 2; (C) Case 3; (D) Case 4; (E) Case 5.

Table 1 Characteristics of Cutaneous Manifestations, Infection and Treatment in Presented Cases

Characteristic	Case 1	Case 2	Case 3	Case 4	Case 5
Age (years)	91	81	79	95	90
Skin lesions	Vesicular	Vesicular	Vesicular	Vesicular	Erythematous
Associated symptoms	Neuropathic pain, intense itching	Intense itching	Not reported	Neuropathic pain	Itching
Skin lesions and associated symptoms treatment	Fexofenadine, topical diflucortolone valerate, gabapentin, buprenorphine transdermal system	Fexofenadine and topical emollients	Topical emollients	Topical diflucortolone valerate, emollients, tramadol, pregabalin	Topical hydrocortisone acetate and emollients
Skin lesions duration (days)	112	21	17	19	27
Timing after testing positive for COVID-19 (days)	32	18	22	19	17
Timing after the resolution of COVID-19 symptoms (days)	18	8	8	9	5
COVID-19 severity	Moderate	Mild	Moderate	Mild	Mild
COVID-19 symptoms	Dry cough, fever, anorexia	Weakness and anorexia	Fever, initially dry then productive cough	Weakness and anorexia	Subfebrile state, weakness, anorexia
COVID-19 treatment	Metamizole, enoxaparin, amikacin and amoxicillin with clavulanic acid	Enoxaparin	Paracetamol, enoxaparin and ceftriaxone	Acenocoumarol	Enoxaparin and amoxicillin with clavulanic acid

Abbreviation: COVID-19, coronavirus disease 2019.